The Future of Preventive Medicine
Why Standard Medicine Is Often Not Enough
Many health risks remain undetected for years—not because they are rare, but because they are often not systematically assessed in conventional preventive screenings. Genetic factors are particularly important in this context, as they influence how our bodies respond to nutrition, exercise, stress, and the ageing process. They help explain why some individuals face an increased risk of certain diseases despite maintaining a healthy lifestyle, while others appear considerably more resilient.
ApoE – An Example of Modern Precision Medicine
One of the most extensively studied genetic factors in preventive medicine is the Apolipoprotein E (ApoE) gene. In particular, the ApoE4 variant has been associated with an increased risk of Alzheimer’s disease, as well as lipid metabolism disorders and atherosclerosis. At the same time, scientific research suggests that individuals with different ApoE variants may respond differently to nutrition, fasting strategies, inflammatory processes, and preventive interventions.
For us, this serves as a compelling example of why modern prevention cannot follow a one-size-fits-all approach. Instead, it requires a deeper understanding of each individual’s biological profile in order to develop truly personalized strategies.
This is why Lanserhof has incorporated the analysis of genetic risk factors into its advanced preventive diagnostics for many years. The goal is not to predict disease, but to gain a better understanding of individual risks and potential. Based on these insights, nutritional concepts, micronutrient strategies, exercise programs, and regenerative therapies can be tailored more precisely to each individual.
Lipoprotein(a) – The Hidden Cardiovascular Risk Factor
Another significant risk factor is Lipoprotein(a), or Lp(a). Elevated levels affect approximately one in five people and can substantially increase the risk of cardiovascular disease—often independently of traditional cholesterol measurements and other established risk markers.
In many cases, Lp(a) is only measured after a heart attack, stroke, or other vascular event has already occurred. At Lanserhof, Lp(a) testing has therefore been part of our advanced preventive assessment for many years. This enables us to identify high-risk individuals early and implement personalized measures long before symptoms emerge.
Prevention Becomes Proactive
Preventive medicine is evolving rapidly. Particularly in the field of Lipoprotein(a), new therapeutic approaches—especially RNA-based therapies—have shown highly promising results. Clinical studies have demonstrated reductions in Lp(a) concentrations of up to 80–90 percent. Whether these substantial reductions will translate into a corresponding decrease in heart attacks and other cardiovascular events is currently being investigated in large international outcome trials.
These developments illustrate a fundamental shift in medicine: away from the purely reactive treatment of established disease and toward the precise identification of individual risk profiles. Modern preventive medicine is no longer solely about detecting disease early. It is about understanding risk, identifying its biological origins, and supporting individuals over many years through targeted interventions.
At Lanserhof, we already assess genetic, metabolic, and cardiovascular risk factors that can often be detected long before symptoms appear. This knowledge not only enables a personalized prevention strategy today but also establishes the foundation for long-term medical guidance.
At the same time, we view prevention as an ongoing process. Scientific discoveries, innovative diagnostic technologies, and therapeutic advances are emerging faster than ever before. Individuals with known risk profiles can therefore continue to benefit from their personal health data over the long term. Those who understand their risks early are best positioned to benefit from future medical innovations as they become available.
We therefore see our role not only as identifying risk factors but as serving as a long-term medical partner. Prevention does not end with diagnosis—it begins there. Understanding individual risks enables informed decisions, targeted interventions, and access to new scientific developments as they emerge.
Our ambition is not to focus on health only once it has been lost. We aim to help people understand their bodies at an earlier stage, make hidden risks visible, and develop personalized strategies for lasting vitality.
The future of medicine lies not only in treating disease. It lies in understanding health more deeply, identifying risks earlier, and making prevention as individual as the people it serves.
